Sanofi, GSK delay COVID-19 vaccine program

Friday, 11. December 2020 07:16

Sanofi S.A. and GlaxoSmithKline plc announced on Friday that their COVID-19 vaccine program has been delayed due to insufficient immune response in the elderly population, so the jab is expected to be available by the last quarter of the next year.

"The results of the study are not as we hoped... Our aim now is to work closely with our partner Sanofi to develop this vaccine, with an improved antigen formulation, for it to make a meaningful contribution to preventing COVID-19," said President of GSK Vaccines, Roger Connor.

The clinical trials are currently in phase 1/2, while phase 2b is set to start in February. If no other setbacks happen, the third and last phase of the trials will start somewhere in the second quarter of 2021.

Related Links: Sanofi S.A.GlaxoSmithKline PLC
Author:
Breaking the News / ND